Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8) 8
adult (7) 7
aged (7) 7
index medicus (7) 7
female (6) 6
male (6) 6
middle aged (6) 6
aged, 80 and over (5) 5
antineoplastic agents - therapeutic use (5) 5
carcinoma, renal cell - drug therapy (5) 5
carcinoma, renal cell (4) 4
care and treatment (4) 4
hematology, oncology and palliative medicine (4) 4
interferon (4) 4
kidney neoplasms - drug therapy (4) 4
oncology (4) 4
risk factors (4) 4
analysis (3) 3
carcinoma, renal cell - secondary (3) 3
clinical trials (3) 3
disease-free survival (3) 3
double-blind (3) 3
medicine, general & internal (3) 3
vascular endothelial growth factor (3) 3
[sdv]life sciences [q-bio] (2) 2
angiogenesis inhibitors - adverse effects (2) 2
angiogenesis inhibitors - therapeutic use (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic agents - adverse effects (2) 2
bevacizumab (2) 2
cancer (2) 2
carcinoma, renal cell - mortality (2) 2
comparative analysis (2) 2
drug therapy (2) 2
efficacy (2) 2
everolimus (2) 2
france - epidemiology (2) 2
imidazoles - adverse effects (2) 2
imidazoles - therapeutic use (2) 2
indazoles - adverse effects (2) 2
indazoles - therapeutic use (2) 2
indoles - therapeutic use (2) 2
interferon-alpha - therapeutic use (2) 2
kaplan-meier estimate (2) 2
kidney neoplasms - mortality (2) 2
kidney neoplasms - pathology (2) 2
life sciences (2) 2
metastasis (2) 2
niacinamide - analogs & derivatives (2) 2
phase-iii trial (2) 2
protein kinase inhibitors - adverse effects (2) 2
protein kinase inhibitors - therapeutic use (2) 2
pyrroles - therapeutic use (2) 2
quality of life (2) 2
receptors, vascular endothelial growth factor - antagonists & inhibitors (2) 2
sunitinib (2) 2
surveillance (2) 2
therapy (2) 2
young adult (2) 2
[ sdv ] life sciences [q-bio] (1) 1
abridged index medicus (1) 1
adolescent (1) 1
agents (1) 1
aids vaccines (1) 1
alphapapillomavirus (1) 1
antibodies, monoclonal, humanized (1) 1
antibody (1) 1
antigen-4 blockade (1) 1
antigens (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antitumor-activity (1) 1
autoimmune diseases - epidemiology (1) 1
autoimmune diseases - etiology (1) 1
autoimmune diseases - immunology (1) 1
autoimmune disorders (1) 1
autoimmunity (1) 1
axitinib (1) 1
bacteremia (1) 1
bacteremia - epidemiology (1) 1
bacteremia - mortality (1) 1
bacterial infections (1) 1
benzenesulfonates - adverse effects (1) 1
benzenesulfonates - therapeutic use (1) 1
biological response modifiers (1) 1
biomarker (1) 1
brain stem (1) 1
carbamates (1) 1
carcinoma (1) 1
carcinoma, renal cell - enzymology (1) 1
case-control studies (1) 1
children (1) 1
clinical medicine (1) 1
clinical trials, phase iii as topic (1) 1
clinical-trials (1) 1
clustering (1) 1
combination (1) 1
complications and side effects (1) 1
confidence (1) 1
connective tissue diseases - immunology (1) 1
ctla-4 (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
by Rini, Brian I, Dr and Escudier, Bernard, MD and Tomczak, Piotr, MD and Kaprin, Andrey, Prof and Szczylik, Cezary, MD and Hutson, Thomas E, DO and Michaelson, M Dror, MD and Gorbunova, Vera A, Prof and Gore, Martin E, Prof and Rusakov, Igor G, Prof and Negrier, Sylvie, Prof and Ou, Yen-Chuan, Prof and Castellano, Daniel, MD and Lim, Ho Yeong, Prof and Uemura, Hirotsugu, Prof and Tarazi, Jamal, MD and Cella, David, PhD and Chen, Connie, PharmD and Rosbrook, Brad, MS and Kim, Sinil, MD and Motzer, Robert J, MD
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9807, pp. 1931 - 1939
Summary Background The treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis. So far, no... 
Internal Medicine | DOUBLE-BLIND | SUNITINIB | MEDICINE, GENERAL & INTERNAL | EFFICACY | CANCER | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Benzenesulfonates - adverse effects | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Angiogenesis Inhibitors - adverse effects | Pyridines - therapeutic use | Imidazoles - adverse effects | Disease-Free Survival | Aged | Indazoles - adverse effects | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Carcinoma, Renal cell | Diagnosis | Research | Drug therapy | Risk factors | Complications and side effects | Axitinib | Dosage and administration | Comparative analysis | Heart attacks | Data collection | Interferon | Family medical history | Clinical medicine | Vascular endothelial growth factor | Drug dosages | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
by Wolchok, Jedd D, Dr and Neyns, Bart, MD and Linette, Gerald, MD and Negrier, Sylvie, Prof and Lutzky, Jose, MD and Thomas, Luc, Prof and Waterfield, William, MD and Schadendorf, Dirk, Prof and Smylie, Michael, Prof and Guthrie, Troy, MD and Grob, Jean-Jacques, Prof and Chesney, Jason, MD and Chin, Kevin, MD and Chen, Kun, PhD and Hoos, Axel, MD and O'Day, Steven J, MD and Lebbé, Celeste, Prof
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 2, pp. 155 - 164
Summary Background Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising activity in advanced... 
Hematology, Oncology and Palliative Medicine | INTERLEUKIN-2 | REGRESSION | METASTATIC MELANOMA | ANTIGEN-4 BLOCKADE | THERAPY | ONCOLOGY | AUTOIMMUNITY | ANTIBODY | CTLA-4 | CONFIDENCE | Skin Neoplasms - pathology | Skin Neoplasms - drug therapy | Double-Blind Method | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Melanoma - pathology | Dose-Response Relationship, Drug | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | Antigens | Medical colleges | Medical research | Care and treatment | Immunotherapy | Melanoma | Monoclonal antibodies | Medicine, Experimental
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
by Motzer, Robert J, Dr and Escudier, Bernard, MD and Tomczak, Piotr, MD and Hutson, Thomas E, DO and Michaelson, M Dror, MD and Negrier, Sylvie, Prof and Oudard, Stephane, Prof and Gore, Martin E, Prof and Tarazi, Jamal, MD and Hariharan, Subramanian, MD and Chen, Connie, PharmD and Rosbrook, Brad, MS and Kim, Sinil, MD and Rini, Brian I, MD
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 552 - 562
Summary Background In a phase 3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell... 
Hematology, Oncology and Palliative Medicine | PROGNOSTIC-FACTORS | EFFICACY | EVEROLIMUS | BIOMARKER | ONCOLOGY | PROGRESSION-FREE SURVIVAL | Niacinamide - analogs & derivatives | Multivariate Analysis | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Carcinoma, Renal Cell - enzymology | Female | Surveys and Questionnaires | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Imidazoles - adverse effects | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - enzymology | Intention to Treat Analysis | Quality of Life | Kidney Neoplasms - pathology | Aged | Indazoles - adverse effects | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Clinical trials | Care and treatment | Carcinoma, Renal cell | Analysis | Patient outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
by Négrier, Sylvie, Prof and Gravis, Gwenaëlle, MD and Pérol, David, MD and Chevreau, Christine, MD and Delva, Rémy, MD and Bay, Jacques-Olivier, Prof and Blanc, Ellen, MSc and Ferlay, Céline, MSc and Geoffrois, Lionnel, MD and Rolland, Frédéric, MD and Legouffe, Eric, MD and Sevin, Emmanuel, MD and Laguerre, Brigitte, MD and Escudier, Bernard, MD
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 7, pp. 673 - 680
Summary Background Combining targeted treatments for renal cell carcinoma has been suggested as a possible method to improve treatment efficacy. We aimed to... 
Hematology, Oncology and Palliative Medicine | TARGETED THERAPY | EVEROLIMUS | ONCOLOGY | CLINICAL-TRIALS | DOUBLE-BLIND | AGENTS | ANTITUMOR-ACTIVITY | COMBINATION | FAILURE | III TRIAL | KIDNEY CANCER | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Humans | Middle Aged | Interferon-alpha - therapeutic use | Antineoplastic Combined Chemotherapy Protocols | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Bevacizumab | Antibodies, Monoclonal, Humanized | Disease-Free Survival | Aged, 80 and over | Adult | Female | Indoles - therapeutic use | Aged | Carcinoma, Renal Cell - drug therapy | Neoplasm Staging | Pyrroles - therapeutic use | Care and treatment | Carbamates | Product development | Interferon | Metastasis | Carcinoma, Renal cell | Biological response modifiers | Vascular endothelial growth factor | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study
by Charlier, Caroline, Dr and Perrodeau, Élodie, MSc and Leclercq, Alexandre, MSc and Cazenave, Benoît, MD and Pilmis, Benoît, MD and Henry, Benoît, MD and Lopes, Amanda, MD and Maury, Mylène M, PhD and Moura, Alexandra, PhD and Goffinet, François, MD and Dieye, Hélène Bracq and Thouvenot, Pierre and Ungeheuer, Marie-Noëlle, MD and Tourdjman, Mathieu, MD and Goulet, Véronique, MD and de Valk, Henriette, MD and Lortholary, Olivier, Prof and Ravaud, Philippe, Prof and Lecuit, Marc, Prof and MONALISA Study Grp and MONALISA study group
Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 5, pp. 510 - 519
Summary Background Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its... 
Infectious Disease | MORTALITY | MENINGITIS | INFECTIOUS DISEASES | MONOCYTOGENES | RISK-FACTORS | MANAGEMENT | GUIDELINES | SURVEILLANCE | PREGNANCY | Foodborne Diseases - microbiology | Infant, Newborn, Diseases - epidemiology | Prognosis | Prospective Studies | Humans | Listeriosis - diagnosis | Bacteremia - mortality | Male | Infant, Newborn, Diseases - microbiology | Listeriosis - epidemiology | Mandatory Reporting | Listeria monocytogenes - classification | Adult | Female | Pregnancy Complications, Infectious - microbiology | Infant, Newborn | Meningoencephalitis - epidemiology | France - epidemiology | Meningoencephalitis - mortality | Pregnancy Complications, Infectious - epidemiology | Risk Factors | Listeria monocytogenes - isolation & purification | Hospitalization | Infectious Disease Transmission, Vertical | Pregnancy | Meningoencephalitis - microbiology | Bacteremia - epidemiology | Listeriosis - microbiology | Aged | Population Surveillance | Listeriosis | Neonates | Food-borne diseases | Disease | Brain stem | Clinical trials | Infections | Genomes | Gestation | Epidemiology | Risk factors | Windows (intervals) | Listeria | Meningitis | Public health | Food | Dexamethasone | Bacterial infections | Mortality | Fetuses | Regression analysis | Clustering | Patients | Bacteremia | Meningoencephalitis | Studies | Surveillance | Medical prognosis | Health risk assessment | Cancer | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
by Motzer, Robert J and Hutson, Thomas E and Tomczak, Piotr and Michaelson, M. Dror and Bukowski, Ronald M and Rixe, Olivier and Oudard, Stéphane and Negrier, Sylvie and Szczylik, Cezary and Kim, Sindy T and Chen, Isan and Bycott, Paul W and Baum, Charles M and Figlin, Robert A
The New England Journal of Medicine, ISSN 0028-4793, 01/2007, Volume 356, Issue 2, pp. 115 - 124
Sunitinib is one of several new antiangiogenic agents undergoing tests of efficacy in the treatment of various types of cancer. Renal-cell carcinoma of the... 
PHASE-III TRIAL | SURVIVAL | MEDICINE, GENERAL & INTERNAL | THERAPY | FUNCTIONAL ASSESSMENT | DOSE RECOMBINANT INTERLEUKIN-2 | VALIDATION | TYROSINE KINASE INHIBITOR | RANDOMIZED-TRIAL | SU11248 | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors | Risk Factors | Interferon-alpha - therapeutic use | Kaplan-Meier Estimate | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Indoles - adverse effects | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Quality of Life | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Interferon-alpha - adverse effects | Kidney Neoplasms - drug therapy | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Interferon alpha | Clinical trials | Interferon | Cytokines | Vascular endothelial growth factor | Skin cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights